Zalicus Report issue

For profit Phase 1 Phase 2
Founded: Vancouver Canada (2009)
Status: Acquired by Sun Pharmaceuticals (2015)

Organization Overview

First Clinical Trial
2009
NCT00747214
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2012

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Zalicus, Inc | Zalicus, Inc.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Arthritis (Phase 2)

Arthritis, Rheumatoid (Phase 2)

Dermatitis (Phase 1)

Dermatitis, Atopic (Phase 1)

Diabetes Mellitus (Phase 2)

Diabetes Mellitus, Type 2 (Phase 2)

Neuralgia (Phase 2)

Neuralgia, Postherpetic (Phase 2)

Osteoarthritis (Phase 2)

Osteoarthritis, Knee (Phase 2)

Psoriasis (Phase 2)

Radiculopathy (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 12
  • # of Trial APIs: 11